Introduction {#ss1}
============

Chronic immune thrombocytopenia (ITP) is an autoimmune disease in which antiplatelet antibodies induce accelerated platelet destruction and impair platelet production resulting in chronically low platelet counts [@b1], [@b2]. Although traditionally the immunologic abnormality in ITP has been ascribed to B-cells and antibody-mediated injury, recent research suggests that a direct toxic effect of T-cells and imbalances in T-cell and cytokine profiles have been observed in some patients with chronic ITP [@b3], [@b4].

Standard care for chronic ITP in adults with a platelet count of at least 30 000/µl involves monitoring without intervention [@b5]. When platelet counts drop below 30 000/µl, corticosteroids can be administered, plus intravenous immunoglobulin (IVIg) if a more rapid rise in platelet count is needed [@b5]. Recently published guidelines suggest using treatment algorithms when patients do not respond to the aforementioned first line therapies, including anti-D immunoglobulin, mycophenolate mofetil and thrombopoietin receptor agonists, among others [@b2].

The increased bleeding risk due to low platelet counts in chronic ITP poses a potentially serious concern during medical and surgical procedures typically associated with bleeding (i.e. hemostatic challenges), whether they are major or minor invasive procedures. However, the use of immunosuppressive medications to increase platelet counts prior to invasive procedures is not ideal, because it may increase the risk of perioperative infection [@b6]. In adults with ITP, treatment guidelines recommend a pre-operative platelet count of at least 50 000/µl before minor surgery and at least 80 000/µl before major surgery [@b2]. Increasing the platelet count can minimize the risk of bleeding, which is the primary goal of treatment in patients with chronic ITP. This also facilitates the undertaking of invasive procedures that would otherwise carry an increased risk of bleeding.

Eltrombopag is an oral, nonpeptide, thrombopoietin-receptor agonist that binds to the transmembrane domain of the thrombopoietin receptor without competing with endogenous thrombopoietin [@b10]. This results in increased proliferation and differentiation of bone marrow progenitor cells into megakaryocytes and increased production of normally functioning platelets [@b10]. Efficacy and safety data from the phase 2 and phase 3 clinical program of eltrombopag in chronic ITP are available from completed and ongoing studies [@b11]. In these studies, eltrombopag increased and maintained platelet counts and reduced bleeding [@b11], [@b12], [@b14], and was shown to reduce the need for concomitant and rescue medications [@b13], [@b15].

This retrospective analysis of data from patients across the eltrombopag clinical program in chronic ITP who underwent hemostatic challenges was conducted to explore platelet counts, use of supplemental ITP treatment, and bleeding events.

Methods {#ss2}
=======

Data were included from five clinical studies of eltrombopag in 494 patients with previously treated chronic ITP. In addition to study treatment (double-blind eltrombopag or placebo, or open-label eltrombopag), all patients received standard care for chronic ITP, in accordance with the investigator\'s usual practice and discretion.

The studies included three randomized, placebo-controlled studies of patients with a baseline platelet count of less than 30 000/µl: Study 773A (*n* = 117) was a 6-week, phase 2, dose-finding study [@b11]; Study 773B (*n* = 114) was a 6-week, phase 3 study [@b12]; and RAISE (*n* = 197) was a 6-month, phase 3 study [@b13]. The other two studies were open-label, single-arm eltrombopag studies: REPEAT (*n* = 66) was a phase 2 study of intermittent treatment (three treatment cycles of up to 6 weeks on therapy and up to 4 weeks off therapy) in patients with baseline platelet counts between 20 000/µl and 50 000/µl [@b14]; and EXTEND is an ongoing extension study for patients who participated in one of the other four studies [@b15]. The cutoff date for this analysis of data from EXTEND was December 2008. Each study was conducted in accordance with the principles contained in the Declaration of Helsinki, each study site received approval from an Institutional Review Board to conduct the study, and each patient provided written informed consent to participate in the study.

Invasive non-dental procedures associated with risk of bleeding were denominated "hemostatic challenges"; minor procedures (e.g. endoscopy, colonoscopy, biopsy) were distinguished from major procedures (e.g. hip arthroplasty, splenectomy, abdominal aneurism repair). Patients were included in this analysis if a non-dental hemostatic challenge was undertaken while the patient was taking study medication (eltrombopag or placebo). Patients were excluded from the analysis if the procedure was more than 10 days after the last dose of study medication, when study treatment was not necessarily expected to influence platelet count or the risk of bleeding events. Information about hemostatic challenges was collected retrospectively in Study 773A and prospectively in the other studies. Investigators were asked to record information about any surgical or medical procedure. Data collection included basic demographic information, platelet counts before and after procedures, type of procedure, need for supplemental ITP treatment to increase platelet counts (from 1 week before through 1 week after the procedure), use of blood products, and information about bleeding events. Supplemental ITP treatments were defined as receiving a new ITP medication, an increase in dose from baseline of a concomitant ITP medication, a platelet or other blood product transfusion, or a splenectomy.

Results {#ss3}
=======

Hemostatic challenges {#ss4}
---------------------

Data were available from 494 patients, including 365 who received eltrombopag and 129 who received placebo in the parent study (773A, 773B, RAISE, or REPEAT). Of these patients, 299 subsequently enrolled in EXTEND and received open-label eltrombopag. A total of 87 hemostatic challenges were recorded ([Figure 1](#F1){ref-type="fig"}), including 44 major procedures in 32 patients and 43 minor procedures in 38 patients; 7 patients had both major and minor procedures. Major procedures are listed by study and patient in [Table I](#T1){ref-type="table"}. Minor procedures are listed by study and patient in [Table II](#T2){ref-type="table"}. Four patients had major procedures during both a parent study (773A, 773B, RAISE, or REPEAT) and in EXTEND, including 3 patients from the eltrombopag group and 1 patient from the placebo group of the parent study ([Table I](#T1){ref-type="table"}). Figure 1.Hemostatic challenges and bleeding events across the eltrombopag ITP clinical program. \*The total of 63 patients includes 7 patients who had both major and minor procedures. †One patient with a hemostatic challenge received placebo in Study 773B and subsequently received open-label eltrombopag in the EXTEND study; this patient underwent a major procedure in each study.

###### 

Major hemostatic challenges during (or within 10 days after) study treatment.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study\         Treatment   Major hemostatic challenge                                    Platelet count (/µl)                                                                                     Supplemental ITP treatment   Bleeding event[^a^](#T1_1){ref-type="fn"}                                                                                                  
  Sex/Age                                                                                                                                                                                                                                                                                                                                                                   
  -------------- ----------- ------------------------------------------------------------- -------------------------------------------------------------------------------------------------------- ---------------------------- ------------------------------------------- --------- ----------------- ----------------------------------------- ------------------------ -----
  **773A**                                                                                                                                                                                                                                                                                                                                                                  

   F/53          50 mg       24                                                            Cholecystectomy                                                                                          15                           428 000                                     29        114 000                                                                              

   F/53          50 mg       29                                                            Laparoscopic cholecystectomy                                                                             22                           369 000                                     36        319 000                                                                              

   F/57^e1^      75 mg       9                                                             Motor vehicle accident                                                                                   8                            491 000                                     57        4000                                                                                 

   F/36          Placebo     19[^b^](#T1_2){ref-type="fn"}                                 Trabeculectomy                                                                                           12                           12 000                                      36        26 000            12,13                                     IVIg                     

  **773B**                                                                                                                                                                                                                                                                                                                                                                  

   M/69          Placebo     29                                                            Hip arthroplasty                                                                                         22                           25 000                                      71        86 000            22,23 29                                  IVIg Transfusion         

   F/27^e2,f1^   Placebo     37                                                            Excision papilloma                                                                                       36                           36 000                                      43        32 000                                                                               

  **RAISE**                                                                                                                                                                                                                                                                                                                                                                 

   M/62^f2^      50 mg       93                                                            Aortic aneurysm repair                                                                                   71                           123 000                                     98        292 000           93                                        Transfusion              

   F/67^f3^      50 mg       119                                                           Tendon sheath incision                                                                                   112                          117 000                                     140       109 000                                                                              

   F/51^f4^      50 mg       107                                                           Hysterectomy                                                                                             105                          175 000                                     132       280 000                                                                              

   F/59^e3^      50 mg       95[^c^](#T1_3){ref-type="fn"} 97[^c^](#T1_3){ref-type="fn"}   Colectomy Laparotomy                                                                                     85 85                        2000 2000                                   211 211   1000 1000         92                                        IVIg                     Yes

   F/18          Placebo     91                                                            Limb operation                                                                                           85                           6000                                        101       9000                                                                                 

  **REPEAT**                                                                                                                                                                                                                                                                                                                                                                

   F/56^e4^      50 mg       48                                                            Sinus operation                                                                                          43                           83 000                                      50        359 000                                                                              Yes

   M/63          50 mg       84                                                            Transurethral prostatectomy                                                                              83                           126 000                                     92        261 000                                                                              

   M/71          50 mg       162[^d^](#T1_4){ref-type="fn"}                                Biopsy pancreas                                                                                          157                          128 000                                     164       77 000                                                                               

   M/48          50 mg       64                                                            Colon polypectomy                                                                                        61                           130 000                                     68        123 000                                                                              

  **EXTEND**                                                                                                                                                                                                                                                                                                                                                                

   F/28^f1^      50 mg       258                                                           Biopsy cervix                                                                                            228                          27 000                                      263       39 000                                                                               

   M/63^f2^      50 mg       93                                                            Hip arthroplasty                                                                                         90                           75 000                                      118       357 000           93                                        Platelet transfusion     

   F/68^f3^      50 mg       141M 141 141 141                                              Cystocele repair Cystopexy Enterocele Vaginal vault prolapse repair                                      135                          412 000                                     148       54 000                                                                               

   F/75^f4^      50 mg       351 351                                                       Carpal tunnel decompression Tendon sheath incision                                                       337                          92 000                                      365       63 000                                                                               

   F/59          50 mg       205                                                           Hip arthroplasty                                                                                         190                          62 000                                      239       116 000           141[^g^](#T1_7){ref-type="fn"} 198, 199   Mycophenolic acid IVIg   

   M/30^e5^      50 mg       474                                                           Splenectomy                                                                                              448                          0                                           484       43 000            465--473                                  Prednisolone             

   M/71          50 mg       511 518                                                       Hip arthroplasty Catheterisation cardiac                                                                 508 508                      79 000 79 000                               536 536   265 000 265 000                                                                      

   M/55          50 mg       449                                                           Incisional drainage                                                                                      442                          85 000                                      467       106 000                                                                              

   F/49          50 mg       204 425                                                       Cataract operation right[^h^](#T1_8){ref-type="fn"} Cataract operation left[^h^](#T1_8){ref-type="fn"}   184 418                      152 000 140 000                             215 448   96 000 165 000                                                                       

   F/50^e6^      50 mg       353                                                           Micrographic skin surgery                                                                                349                          88 000                                      358       94 000                                                                               

   F/54          50 mg       312                                                           Splenectomy                                                                                              308                          90 000                                      332       44 000                                                                               

   F/52^e7^      50 mg       150                                                           Medical device implantation                                                                              87                           19 000                                      --        --                                                                                   

   F/65          50 mg       293                                                           Ovarian operation                                                                                        286                          108 000                                     309       208 000                                                                              

   F/68          50 mg       176 204                                                       Cataract operation[^i^](#T1_9){ref-type="fn"} Cataract operation[^i^](#T1_9){ref-type="fn"}              175 189                      88 000 74 000                               182 210   48 000 54 000                                                                        

   F/65          50 mg       71                                                            Cataract operation[^h^](#T1_8){ref-type="fn"}                                                            56                           16 000                                      78        158 000                                                                              

   F/38          50 mg       172                                                           Uterine polypectomy                                                                                      155                          117 000                                     183       174 000                                                                              

   F/76          50 mg       548                                                           Femur fracture                                                                                           540                          89 000                                      575       76 000                                                                               

   F/75          50 mg       216                                                           Carpal tunnel decompression                                                                              210                          205 000                                     224       76 000                                                                               

   M/42          50 mg       123                                                           Arthroscopy                                                                                              122                          42 000                                      150       35 000                                                                               

   F/57          50 mg       98                                                            Splenectomy                                                                                              98                           256 000                                     99        328 000                                                                              

   F/46          50 mg       468                                                           Hemorrhoid operation                                                                                     460                          264 000                                     467       38 000                                                                               
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

See text for details of reported bleeding adverse events.

Patients were still on study at the time of the hemostatic challenge, except as follows:

study medication had stopped on day 12 to switch patient to IVIg prior to operation;

study medication had stopped on day 91 due to adverse event;

study medication had stopped on day 157 for unspecified reason.

Seven patients (labeled e1 to e7 in this table and in [Table II](#T2){ref-type="table"}) underwent a major procedure and a minor procedure.

Four patients (labeled f1 to f4) underwent a major procedure in both a parent study and in the EXTEND study.

Supplemental ITP treatment was ongoing at the time of study completion on day 253.

Cataracts were present at baseline in this patient and were not considered related to eltrombopag treatment.

Cataracts were present at baseline in this patient and worsening of cataracts was considered related to eltrombopag treatment.

###### 

Minor hemostatic challenges during (or within 10 days after) study treatment.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study\       Treatment   Minor hemostatic challenge                                    Platelet count (/µl)                 Supplemental ITP treatment                                                                      
  Sex/Age                                                                                                                                                                                                                     
  ------------ ----------- ------------------------------------------------------------- ------------------------------------ ---------------------------- ---------------- --------- --------------- ----------------------- ------------------------------------
  **RAISE**                                                                                                                                                                                                                   

   F/59^e1^    50 mg       87                                                            Colonoscopy                          85                           2000             211       1000                                    

   F/80        50 mg       10                                                            Skin lesion                          8                            49 000           17        163 000           1--11                 Prednisone

   F/47        50 mg       16[^a^](#T2_1){ref-type="fn"}                                 Lumbar puncture                      16                           339 000          21        375 000           83--91                Methylprednisolone

   F/48        50 mg       82                                                            Lumbar puncture                      78                           79 000           96        17 000            86 87                 Anti-D Ig Transfusion

   M/52        50 mg       54[^b^](#T2_2){ref-type="fn"} 93[^b^](#T2_2){ref-type="fn"}   Endoscopy (GI) Endoscopy (GI)        50 50                        34 000 34 000    105 105   31 000 31 000                           

   F/47        50 mg       166 166                                                       Biopsy Skin operation                160                          342 000          168       365 000                                 

   F/72        50 mg       114                                                           Skin biopsy                          111                          180 000          118       190 000                                 

   F/33        Placebo     141                                                           Bone marrow biopsy                   141                          20 000           155       21 000                                  

  **REPEAT**                                                                                                                                                                                                                  

   F/56        50 mg       41                                                            Colonoscopy                          36                           101 000          43        112 000                                 

   F/59        50 mg       111                                                           Endoscopy (upper GI)                 106                          528 000          113       280 000                                 

   F/53        50 mg       113                                                           Colonoscopy                          106                          107 000          114       85 000                                  

  **EXTEND**                                                                                                                                                                                                                  

   F/58^e2^    50 mg       210 252                                                       Bronchoscopy Bone marrow biopsy      209 252                      227 000 29 000   215 256   44 000 20 000   250--251                IVIg

   F/49^e3^    50 mg       396                                                           Bone marrow biopsy                   396                          46 000           425       56 000                                  

   F/57^e4^    50 mg       334                                                           Colonoscopy                          329                          139 000          369       168 000                                 

   M/30^e5^    50 mg       386 462                                                       Bone marrow biopsy Lumbar puncture   386 448                      0 0              420 484   0 43 000        463                     IVIg

   F/50^e6^    50 mg       211                                                           Skin biopsy                          202                          80 000           230       87 000                                  

   F/52^e7^    50 mg       130                                                           Dialysis                             87                           19 000           ---       ---                                     

   F/56        50 mg       102                                                           Endoscopy                            101                          3000             113       975 000         96, 101--105 101--104   IVIg Dexamethasone

   M/54        50 mg       56                                                            Colonoscopy                          56                           87 000           62        102 000                                 

   F/70        50 mg       353                                                           Endoscopy (upper GI)                 337                          209 000          365       189 000                                 

   F/82        50 mg       471                                                           Colonoscopy                          461                          36 000           489       140 000                                 

   F/61        50 mg       15                                                            Colonoscopy                          8                            204 000          17        510 000                                 

   F/80        50 mg       29                                                            Skin neoplasm excision               29                           268 000          34        208 000                                 

   M/78        50 mg       389[^c^](#T2_3){ref-type="fn"}                                Endoscopy                            387                          248 000          400       185 000                                 

   F/49        50 mg       42                                                            Bone marrow biopsy                   42                           28 000           48        26 000                                  

   F/65        50 mg       131                                                           Colonoscopy                          127                          96 000           134       265 000                                 

   M/68        50 mg       313                                                           Acrochordon excision                 288                          56 000           316       68 000                                  

   F/22        50 mg       348                                                           Endoscopy (upper GI)                 344                          156 000          351       76 000                                  

   F/45        50 mg       83[^d^](#T2_4){ref-type="fn"}                                 Stem cell transplant                 82                           41 000           89        29 000          74--79 75--97 80        Transfusion Prednisolone Anti-D Ig

   F/45        50 mg       656                                                           Tissue sealing                       649                          54 000           670       164 000                                 

   F/55        50 mg       100                                                           Endoscopy (upper GI)                 100                          100 000          108       29 000                                  

   F/51        50 mg       414                                                           Bone marrow biopsy                   414                          88 000           443       77 000                                  

   F/68        50 mg       406                                                           Bone marrow biopsy                   406                          5000             416       2000                                    

   F/47        50 mg       31                                                            Bone marrow biopsy                   31                           77 000           37        61 000          32--60                  Prednisolone

   F/53        50 mg       19                                                            Suture insertion                     19                           450 000          31        6000                                    

   F/57        50 mg       227                                                           Tumor excision                       225                          64 000           232       73 000          221--224                Methylprednisolone

   F/60        50 mg       402                                                           Bone marrow biopsy                   388                          159 000          409       123 000                                 

   F/43        50 mg       85 85                                                         Colonoscopy Endoscopy (upper GI)     82                           82 000           92        74 000                                  
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

No bleeding adverse events were reported after minor hemostatic challenges.

Patients were still on study at the time of the hemostatic challenge, except as follows:

study medication was stopped on day 15 due to adverse event;

study medication was stopped on day 53 due to adverse event;

study medication was stopped on day 387 due to adverse event;

study medication was stopped on day 75 due to lack of efficacy.

Seven patients (labeled e1 to e7 in this table and in [Table I](#T1){ref-type="table"}) underwent a major procedure and a minor procedure.

Platelet counts {#ss5}
---------------

Platelet counts at the last assessment before hemostatic challenge are summarized in [Table III](#T3){ref-type="table"}. Before major hemostatic challenges, median platelet counts were 100 000/µl (range, 0--491 000/µl) in the eltrombopag group and 18 500/µl (range, 6000--36 000/µl) in the placebo group. Before minor hemostatic challenges, median platelet counts were 82 000/µl (range, 0--528 000/µl) in the eltrombopag group and 20 000/µl (only one procedure) in the placebo group. One patient had platelet counts of 0 reported before three hemostatic challenges, including bone marrow biopsy on day 386 ([Table II](#T2){ref-type="table"}), lumbar puncture on day 448 ([Table II](#T2){ref-type="table"}), and splenectomy on day 474 ([Table I](#T1){ref-type="table"}). Table III. Median platelet count (range) at the last assessment before the procedure.Type of procedureStudy treatmentNo. of subjectsPlatelet count, µl median (range)MajorEltrombopag29100 (0--491)Placebo418.5 (6--36)MinorEltrombopag3782 (0--528)Placebo120 (NA)[^1]

Supplemental ITP treatment {#ss6}
--------------------------

Among the patients who underwent a major hemostatic challenge, supplemental ITP treatment was administered to 4 of 29 patients in the eltrombopag group (including 1 in RAISE, 2 in EXTEND, and 1 in both RAISE and EXTEND) and 2 of 4 patients in the placebo group. Among the patients with minor hemostatic challenges, supplemental ITP treatment was administered to 9 of 37 patients in the eltrombopag group (including 3 in RAISE and 6 in EXTEND) and was not administered to the 1 patient in the placebo group.

Bleeding events {#ss7}
---------------

No patient had a bleeding event after a minor procedure. No bleeding events were reported among the 5 placebo-treated patients. Two patients who received eltrombopag had bleeding events reported up to 2 days after major procedures, as follows.

One patient in the REPEAT study underwent sinus surgery (endoscopic sinus surgery with balloon sinuplasty and balloon dilation) on day 13 of the on-therapy period of the second treatment cycle. The platelet count at the start of the second treatment cycle was 28 000/µl and 5 days before the surgery it was 83 000/µl. The patient experienced a post-procedural bleeding event beginning on the day of surgery, described by the investigator as "bloody nasal discharge post surgery" and considered it to be mild and not related to study treatment. No rescue treatment was reported and the patient continued to take eltrombopag once daily. The platelet count 2 days after the surgery was 359 000/µl without supplemental ITP treatment; because the platelet count was \>200 000/µl, eltrombopag treatment was interrupted and the off-therapy period of the cycle began.

One patient in RAISE, who did not respond to treatment with eltrombopag (platelet count range, 2000/µl to 29 000/µl), presented with rectal bleeding and a platelet count of 2000/µl after 87 days on study. A colonoscopy with biopsy demonstrated a colorectal adenocarcinoma. Eltrombopag was interrupted, IVIg was initiated, and a colectomy was performed on study day 95, with no prophylactic anticoagulation. On day 96, the patient experienced a bilateral pulmonary embolism, which required anticoagulation with heparin. On day 97, the patient experienced intra-abdominal bleeding, which required red blood cell transfusion and a laparotomy for hemostasis. Platelet counts were not available at the time of these events. The post operative course was subsequently unremarkable. After completing her participation in RAISE the patient entered EXTEND, where she responded to open-label eltrombopag. On day 334 of EXTEND, the patient underwent a colonoscopy with a pre-procedural platelet count of 139 000/µl without supplemental ITP treatment and no bleeding event was reported after this procedure.

Discussion {#ss8}
==========

In this analysis of data from five studies of eltrombopag in patients with chronic ITP, patients treated with eltrombopag had median platelet counts of 100 000/µl before major invasive procedures and 82 000/µl before minor procedures. These findings are in line with recent clinical guidelines for the identification and management of ITP [@b2], which recommend a target platelet count of at least 80 000/µl before a major procedure and at least 50 000/µl before a minor procedure. None of the patients who had received placebo and underwent a hemostatic challenge had platelet levels above these targets prior to the procedures. Although none of the 4 patients in the placebo group who underwent a major procedure had a bleeding event recorded, 2 of them required supplemental ITP treatment. Because of the retrospective nature of this analysis, it was not possible to determine how many patients in either treatment group required a minor or major procedure but were not eligible due to low platelet counts.

The primary goal of increasing platelet counts in patients with chronic ITP is to reduce bleeding events. Few bleeding events were reported in this analysis, which adequately correlates to the acceptable pre-procedural platelet counts. No difference in the use of peri-procedural blood products between groups was apparent, which can possibly be correlated to the acceptable platelet counts and low frequency of bleeding events reported. However, given that the studies were not specifically designed to investigate these endpoints, the number of patients who were not able to undergo procedures due to thrombocytopenia was not captured, which limits the conclusions that can be drawn from this analysis.

Conclusion {#ss9}
==========

In five phase 2 and phase 3 studies of eltrombopag in patients with previously treated chronic ITP, eltrombopag was associated with sustained increases in platelet counts and reductions in bleeding events [@b11], [@b12], [@b14] and reduced the need for concomitant and rescue medications [@b13], [@b15]. Data from the 87 hemostatic challenges that were reported in these studies suggest that the majority of patients with chronic ITP who are treated with eltrombopag and experience increases in platelet counts will achieve the platelet count recommendations to undertake invasive procedures, potentially reducing the risk of bleeding complications and the need for additional ITP treatment. The potential role of eltrombopag in supporting the preparation of chronic ITP patients for surgical procedures still needs to be clinically established.
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